translation to dogs is uncertain Lack of clinical trials: No published randomized controlled trials in dogs Regulatory status: Not approved by FDA or veterinary regulatory agencies Quality control: Variability in peptide quality from research suppliers Optimal protocols: Dose, frequency, duration, and timing relative to injury not established for dogs Outcome measures: Standardized assessment of improvement in dogs lacking Long-term effects: Unknown effects of chronic use in companion animals Complementary Approaches to Canine Orthopedic Care Established evidence-based interventions for canine orthopedic conditions include: Weight management: Critical for reducing joint stress and improving outcomes Physical rehabilitation: Therapeutic exercises, hydrotherapy, and passive range of motion NSAIDs: Carprofen, meloxicam, and other veterinary anti-inflammatories Joint supplements: Glucosamine, chondroitin sulfate, omega-3 fatty acids Regenerative medicine: Platelet-rich plasma (PRP), stem cell therapy Surgical interventions: Various procedures depending on specific condition Assistive devices: Braces, slings, carts for mobility support Acupuncture and laser therapy: Adjunctive pain management modalities The Veterinary Research Landscape Peptide research in veterinary medicine faces unique challenges: Limited funding compared to human medical research Smaller market size for veterinary pharmaceuticals Regulatory pathways less established than for human drugs Ethical considerations for experimental treatments in companion animals Need for breed-specific and size-specific data given canine diversity Despite these challenges, there is growing interest in translating peptide research to veterinary applications, particularly for conditions with limited treatment options
10.1667/0033-7587(2000)153[0173:motopb]2.0.co;2 267 WormD
EDS is characterized in its most common form by hyperextensibility of the skin, hypermobility of joints often resulting in dislocations, and tissue fragility exemplified by easy bruising, atrophic scars following superficial injury, and premature rupture of membranes during pregnancy
Modern GLP-1/GIP agonism is potent enough that adding phentermine adds risk rather than benefit for most patients
Current safety data for 5-amino-1MQ appears favorable for short-term use (8-12 week cycles), with no significant toxicity observed in preclinical studies at therapeutic doses
Plateau Busting Weight loss plateaus are nearly universal during long-term peptide use
